Payment overview · 2025
General Payments
We did not find matching Open Payments records for this doctor in the selected program year.
Healthcare provider profile · identity verified
Physical Medicine and Rehabilitation · WEST SENECA, NY · NPI 1891769436
Verified facts
We did not find matching Open Payments records for this doctor in 2025.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
We did not find matching Open Payments records for this doctor in the selected program year.
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Analysis 1 · Payment-linked products
No payment-linked product analysis is available because no matching General Payment records were found for the selected year.
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
There is no payer-company set available for this comparison.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Risperidone | Risperidone | 309 | 46 |
| Olanzapine | Olanzapine | 212 | 34 |
| Lorazepam | Lorazepam | 209 | 53 |
| Sertraline Hcl | Sertraline Hcl | 195 | 29 |
| Divalproex Sodium | Divalproex Sodium | 113 | 17 |
| Clonazepam | Clonazepam | 109 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 13 |
| Aripiprazole | Aripiprazole | 105 | 18 |
| Lithium Carbonate | Lithium Carbonate | 94 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 11 |
| Lamotrigine | Lamotrigine | 93 | 13 |
| Buspirone Hcl | Buspirone Hcl | 84 | 12 |
| Clozapine | Clozapine | 82 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 74 | 12 |
| Propranolol Hcl | Propranolol Hcl | 60 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Haloperidol | Haloperidol | 54 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 49 | 11 |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 45 | suppressed |
| Amantadine | Amantadine Hcl | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 39 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 33 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Gabapentin | Gabapentin | 13 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | — | — | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error